Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 6/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696888 | 0.82 | NOS3 (0.53) | DAGLADRD2DRD4DRD3DAGLB | |
| SCHEMBL6701137 | 0.79 | SPHK1 (0.42) | DAGLASPHK1DRD2DRD4DRD3 | |
| SCHEMBL6701134 | 0.77 | DAGLA (0.39) | DAGLASPHK1DRD2DRD4DRD3 | |
| SCHEMBL27492 | 0.76 | — | — | |
| SCHEMBL6700239 | 0.75 | DRD2 (0.47) | DRD2DRD4DRD3 | |
| Ammonia Solution, Strong SCHEMBL7288994 | 0.75 | — | — | |
| SCHEMBL11470279 | 0.75 | — | — | |
| SCHEMBL6703073 | 0.75 | DRD2 (0.47) | DRD2DRD4DRD3 | |
| SCHEMBL6702595 | 0.73 | NOS1 (0.58) | DRD2DRD4DRD3 | |
| SCHEMBL5530480 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER INC | 2004-07-22 | — | — | US | disclosed |
| EP-0946512-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-03-14 | — | — | US | disclosed |
| US-6235750-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC | 2001-05-22 | — | — | US | disclosed |
| EP-0946512-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024766-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | DAGLA 4136/4885SPHK1 1917/4885DRD2 661/4885 |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | DAGLA 4136/4885SPHK1 1917/4885DRD2 661/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | DAGLA 3287/4885SPHK1 360/4885DRD2 255/4885 |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | DAGLA 4136/4885SPHK1 1917/4885DRD2 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.